Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

V. Hird, A. Maraveyas, D. Snook, B. Dhokia, W. P. Soutter, C. Meares, J. S W Stewart, P. Mason, H. E. Lambert, A. A. Epenetos

Research output: Contribution to journalArticle

151 Citations (Scopus)

Abstract

Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-11 study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.

Original languageEnglish (US)
Pages (from-to)403-406
Number of pages4
JournalBritish Journal of Cancer
Volume68
Issue number2
StatePublished - Aug 1993

Fingerprint

Ovarian Neoplasms
Monoclonal Antibodies
pemtumomab
Yttrium
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hird, V., Maraveyas, A., Snook, D., Dhokia, B., Soutter, W. P., Meares, C., ... Epenetos, A. A. (1993). Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. British Journal of Cancer, 68(2), 403-406.

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. / Hird, V.; Maraveyas, A.; Snook, D.; Dhokia, B.; Soutter, W. P.; Meares, C.; Stewart, J. S W; Mason, P.; Lambert, H. E.; Epenetos, A. A.

In: British Journal of Cancer, Vol. 68, No. 2, 08.1993, p. 403-406.

Research output: Contribution to journalArticle

Hird, V, Maraveyas, A, Snook, D, Dhokia, B, Soutter, WP, Meares, C, Stewart, JSW, Mason, P, Lambert, HE & Epenetos, AA 1993, 'Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody', British Journal of Cancer, vol. 68, no. 2, pp. 403-406.
Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. British Journal of Cancer. 1993 Aug;68(2):403-406.
Hird, V. ; Maraveyas, A. ; Snook, D. ; Dhokia, B. ; Soutter, W. P. ; Meares, C. ; Stewart, J. S W ; Mason, P. ; Lambert, H. E. ; Epenetos, A. A. / Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. In: British Journal of Cancer. 1993 ; Vol. 68, No. 2. pp. 403-406.
@article{2100121a02a64544a56a5a7d5464a5ee,
title = "Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody",
abstract = "Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-11 study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.",
author = "V. Hird and A. Maraveyas and D. Snook and B. Dhokia and Soutter, {W. P.} and C. Meares and Stewart, {J. S W} and P. Mason and Lambert, {H. E.} and Epenetos, {A. A.}",
year = "1993",
month = "8",
language = "English (US)",
volume = "68",
pages = "403--406",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

AU - Hird, V.

AU - Maraveyas, A.

AU - Snook, D.

AU - Dhokia, B.

AU - Soutter, W. P.

AU - Meares, C.

AU - Stewart, J. S W

AU - Mason, P.

AU - Lambert, H. E.

AU - Epenetos, A. A.

PY - 1993/8

Y1 - 1993/8

N2 - Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-11 study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.

AB - Fifty-two patients with epithelial ovarian cancer were treated with yttrium-90-labelled monoclonal antibody HMFG1 administered intraperitoneally following conventional surgery and chemotherapy as part of an extended phase I-II trial. The treatment was well tolerated and the only significant toxicity observed was reversible myelosuppression as previously described. Following conventional surgery and chemotherapy, 21 out of the 52 patients had no evidence of residual disease and were regarded as receiving treatment in an adjuvant setting. To date, two of these patients have died of their disease (follow-up 3-62 months, median follow-up 35 months). This extended phase I-11 study suggests that patients with advanced ovarian cancer who achieve a complete remission following conventional therapy may benefit from further treatment with intraperitoneal radioactive monoclonal antibody.

UR - http://www.scopus.com/inward/record.url?scp=0027219075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027219075&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 403

EP - 406

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -